Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HeartWare Points To Less Acute Patients As One Key To HVAD Success

This article was originally published in The Gray Sheet

Executive Summary

As HeartWare awaits an approval decision for its first left ventricular assist device, the company says it is continuing to advance its pipeline and push forward with a longer-term strategy to maximize the treatable population for the product.

You may also be interested in...

FDA Holds Up HeartWare LVAD Trial In Less Advanced Heart Failure Patients

Investigators for the REVIVE-IT pilot study received a second deficiency letter from FDA May 11; researchers say they continue to work with the agency to move forward on the 100-patient, randomized trial.

News In Brief

Novartis buys Genoptix

HeartMate Meets Its Match? HeartWare VAD Data Has Good Showing At AHA

Thoratec's days monopolizing the ventricular assist device market with its HeartMate VAD technology appear to be numbered. That's the consensus out of last week's American Heart Association annual meeting, where upstart HeartWare reported impressive results for its next-generation VAD in late-stage heart failure patients waiting for a transplant.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts